Stock A002390 HANDOK INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials HANDOK Inc.

Equities

A002390

KR7002390003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 20/05/2024 BST 		5-day change 1st Jan Change
13,520 KRW -0.29% Intraday chart for HANDOK Inc. -0.95% -5.45%
04-16 Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea, MT
04-15 Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 418,055 311,744 458,326 313,809 230,539 196,819
Enterprise Value (EV) 1 543,979 496,560 658,619 536,764 488,981 476,774
P/E ratio 52.1 x 8.9 x 17 x 95.4 x 21.6 x -6.84 x
Yield 1.47% 1.21% 0.9% 1.54% 2.39% 2.1%
Capitalization / Revenue 0.94 x 0.66 x 0.91 x 0.61 x 0.42 x 0.38 x
EV / Revenue 1.22 x 1.05 x 1.31 x 1.04 x 0.9 x 0.91 x
EV / EBITDA 13 x 10.1 x 13.2 x 10.9 x 9.73 x 13.6 x
EV / FCF 27.3 x -22.8 x -456 x 73.4 x -14.4 x 177 x
FCF Yield 3.66% -4.39% -0.22% 1.36% -6.94% 0.56%
Price to Book 1.36 x 0.91 x 1.2 x 0.82 x 0.61 x 0.58 x
Nbr of stocks (in thousands) 13,617 13,764 13,764 13,764 13,764 13,764
Reference price 2 30,700 22,650 33,300 22,800 16,750 14,300
Announcement Date 15/03/19 03/03/20 18/03/21 16/03/22 09/03/23 14/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 446,731 473,000 503,612 517,641 543,759 522,741
EBITDA 1 41,985 49,032 49,830 49,374 50,255 35,067
EBIT 1 22,075 27,452 28,376 28,006 28,496 12,579
Operating Margin 4.94% 5.8% 5.63% 5.41% 5.24% 2.41%
Earnings before Tax (EBT) 1 9,344 48,470 42,128 4,768 7,316 -33,508
Net income 1 7,990 34,929 26,960 3,295 10,684 -28,797
Net margin 1.79% 7.38% 5.35% 0.64% 1.96% -5.51%
EPS 2 589.0 2,544 1,958 239.0 775.9 -2,091
Free Cash Flow 1 19,933 -21,809 -1,444 7,308 -33,947 2,692
FCF margin 4.46% -4.61% -0.29% 1.41% -6.24% 0.51%
FCF Conversion (EBITDA) 47.48% - - 14.8% - 7.68%
FCF Conversion (Net income) 249.49% - - 221.81% - -
Dividend per Share 2 450.0 275.0 300.0 350.0 400.0 300.0
Announcement Date 15/03/19 03/03/20 18/03/21 16/03/22 09/03/23 14/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 125,924 184,816 200,293 222,956 258,442 279,956
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.999 x 3.769 x 4.02 x 4.516 x 5.143 x 7.983 x
Free Cash Flow 1 19,933 -21,809 -1,444 7,308 -33,947 2,692
ROE (net income / shareholders' equity) 2.34% 10.3% 7.43% 0.86% 2.77% -8.01%
ROA (Net income/ Total Assets) 2.14% 2.45% 2.26% 2.11% 2.08% 0.95%
Assets 1 374,094 1,426,361 1,191,482 156,286 513,681 -3,043,162
Book Value Per Share 2 22,573 24,816 27,703 27,900 27,596 24,611
Cash Flow per Share 2 2,387 1,311 1,722 2,212 2,677 1,203
Capex 1 15,767 22,032 20,438 43,018 36,205 19,208
Capex / Sales 3.53% 4.66% 4.06% 8.31% 6.66% 3.67%
Announcement Date 15/03/19 03/03/20 18/03/21 16/03/22 09/03/23 14/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HANDOK INC. Stock HANDOK Inc.
-5.45% 137M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.78% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.82% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 332B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.64% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-4.13% 210B
NOVARTIS AG Stock Novartis AG
+10.63% 209B
AMGEN INC. Stock Amgen Inc.
+9.32% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A002390 Stock
  4. Financials HANDOK Inc.